Fine Particulate Matter Linked to Increased Incidence of Head, Neck Cancer
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 21, 2024 -- Exposure to air pollution in the form of particulate matter measuring less than 2.5 µm (PM2.5) is associated with an increased incidence of head and neck cancer, according to a study published online Nov. 12 in Scientific Reports.
John Peleman, M.D., from Wayne State University in Detroit, and colleagues examined the effect of PM2.5 on head and neck aerodigestive cancer incidence in a cohort analysis using data from the Surveillance, Epidemiology, and End Results national cancer database from 2002 to 2012. A linear mixed model was used to assess the relationship between U.S. county mean PM2.5 levels and head and neck cancer incidence rates.
The researchers found that after controlling for demographic characteristics, smoking, and alcohol use, there was a significant association between head and neck cancer incidence and certain subtypes with PM2.5 exposure. The highest association was seen at a five-year lag period (β = 0.24). Significant associations were also seen at no lag and up to a 20-year lag period (β = 0.16 and 0.15, respectively).
"With increasing importance on environmental health and preventative medicine, this study adds to the expanding body of literature that supports improved air quality standards to mitigate the effects of air pollution on development of cancer, including head and neck cancer," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-22 12:00
Read more
- Metformin Beneficial in Lung Cancer Patients With Overweight, Obesity
- Stroke Guidelines Updated, With Focus on Women and GLP-1s
- Wildfire Smoke Exposure Linked to Dementia Risk
- Infertility Without Treatment Linked to Autoimmune Rheumatic Disease After Childbirth
- In Mouse Studies, New Hope Against a Dangerous Complication of Pregnancy
- Biden Will Move to Have Medicare, Medicaid Cover GLP-1 Weight-Loss Meds, such as Wegovy, Zepbound
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions